RESUMO
The data obtained on 68 patients suffering from cardiac arrhythmia treated with bonnecor or ethacizine demonstrate that bonnecor corrects ventricular extrasystole including high-grade arrhythmia in 80.4% of the patients while ethacizine in 84.6%. Acute tests with the drugs can effectively prognosticate the outcomes of bonnecor or ethacizine long-term treatment. The drugs eliminate delta-wave and stimulation-induced arrhythmias in 90% and 44-56% of patients with WPW syndrome, respectively. Bonnecor is less effective in nodal tachycardia. Both the drugs noticeably suppress conductivity.
Assuntos
Antiarrítmicos/uso terapêutico , Fibrilação Atrial/tratamento farmacológico , Complexos Cardíacos Prematuros/tratamento farmacológico , Dibenzazepinas/uso terapêutico , Fenotiazinas/uso terapêutico , Taquicardia Supraventricular/tratamento farmacológico , Adolescente , Adulto , Idoso , Humanos , Pessoa de Meia-IdadeRESUMO
The protective and therapeutic effects of some antiarrhythmic drugs of classes I-IV were studied in the experiments on 103 cats and 75 dogs. The antiarrhythmic drugs of classes 1a (N-propylaimaline bromide, aimaline, ethacizine), 1b (trimecaine) and IV (finoptine) were shown to prevent with various effectiveness the occurrence of early occlusion and reperfusion ventricular arrhythmias. The antiarrhythmic drugs of classes II (anapriline) and III (cordaron) proved to be ineffective in these cases. Ventricular arrhythmia in dogs occurring at the late stage of experimental infarction is reliably relieved in all cases with the antiarrhythmic drugs of class 1a, in most cases--those of classes 1b and III. The antiarrhythmic drugs of classes II and III are ineffective on this model. The experimental results analysed with regard to modern concepts of the genesis of modelled arrhythmias may be used as the experimental basis for a rational choice of antiarrhythmic drugs.
